Impact of Obesity on Warfarin Reversal With Fixed-Dose Factor VIII Inhibitor Bypassing Activity (aPCC).

CONCLUSION AND RELEVANCE: When fixed-dose aPCC is used for warfarin reversal, obesity is associated with a significantly lower rate of INR reversal, without increased bleeding. This study adds to the limited amount of literature on aPCC dosing in obesity.
PMID: 33094635 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - October 23, 2020 Category: Drugs & Pharmacology Authors: McKinney AL, Dailey LM, McMillen JC, Rowe AS Tags: Ann Pharmacother Source Type: research